On the earnings front, the company, on May 7, posted GAAP first-quarter net income of $1.029 million, while ongoing operations Adjusted EBITDA came in at $1,494 million.Cramer said, “I kept thinking that there would be a consolidator and Stryker (NYSE:SYK) would do the consolidating.” However, that has not come to pass.On June 5, Leerink Partners analyst Mike Kratky maintained Stryker with an Outperform rating and lowered the price target from $410 to $407.Cramer said he likes Fair Isaac Corporation (NYSE:FICO), but he is not going to go there: “I'm not going to get in the crosshairs anymore of these companies that might get hurt by AI. It's too painful.”Fair Isaac announced a $2 billion buyback plan on June 8.On June 11, UBS analyst Jonathan Yong maintained Clover Health Investments at Neutral and raised the price target from $2.75 to $4.75.Price Action
Fair Isaac shares fell 5% to settle at $1,126.84 on Wednesday.
Clover Health Investments shares fell 2.8% to close at $4.80.
Vistra shares rose 0.1% to close at $158.83 on Wednesday.
Stryker shares declined 3% to settle at $301.14.
